UCB (UNC) Stock Overview
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
UNC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
UCB SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €234.40 |
| 52 Week High | €260.20 |
| 52 Week Low | €203.00 |
| Beta | 0.22 |
| 1 Month Change | -1.47% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 533.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| UNC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.9% | 7.2% | 2.3% |
| 1Y | n/a | -0.7% | 12.6% |
Return vs Industry: Insufficient data to determine how UNC performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how UNC performed against the German Market.
Price Volatility
| UNC volatility | |
|---|---|
| UNC Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: UNC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine UNC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 8,600 | Jean-Christophe Tellier | www.ucb.com |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
UCB SA Fundamentals Summary
| UNC fundamental statistics | |
|---|---|
| Market cap | €45.18b |
| Earnings (TTM) | €1.33b |
| Revenue (TTM) | €6.85b |
Is UNC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UNC income statement (TTM) | |
|---|---|
| Revenue | €6.85b |
| Cost of Revenue | €1.82b |
| Gross Profit | €5.03b |
| Other Expenses | €3.69b |
| Earnings | €1.33b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Feb 26, 2026
| Earnings per share (EPS) | 7.01 |
| Gross Margin | 73.38% |
| Net Profit Margin | 19.45% |
| Debt/Equity Ratio | 27.7% |
How did UNC perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 11:48 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
UCB SA is covered by 46 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Bourdot | Barclays |
| Charles Pitman | Barclays |
| Kerry Holford | Berenberg |